Browse Drug Recalls
6,306 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 6,306 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 6,306 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Mar 19, 2021 | BD ChloraPrep Clear, 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isoprop... | Non-sterility.Product is being recalled because at labeled storage conditions of 30*C/75% Relativ... | Class I | CareFusion 213, LLC |
| Mar 11, 2021 | Phenylephrine HCl Injection, USP, 10 mg per mL, 1 mL per Single-Dose Vial pac... | Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may res... | Class II | Sagent Pharmaceuticals Inc |
| Feb 17, 2021 | Fludeoxyglucose F 18 Injection, 20-300 mCi/mL at End of Synthesis (EOS) Solut... | Lack of Assurance of Sterility | Class II | The General Hospital Corporation |
| Feb 10, 2021 | Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), pa... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | MethyIPREDNISolone Acetate Injectable Suspension USP, 80 mg/mL, 1 mL Single-D... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL),... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Leucovorin Calcium for Injection, USP, 100 mg/vial, Single-Dose Vial, Rx only... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Epoprostenol Sodium for Injection, 0.5 mg/vial (500,000 ng), 1X10ML vial, Rx... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL)... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Toposar (etoposide injection USP), 1 gram/50 mL (20 mg/mL), 50 mL Multiple-do... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | MethyIPREDNISolone Acetate Injectable Suspension USP, 200 mg/5 mL (0 mg/mL), ... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Vecuronium Bromide for Injection, 10 mg, 1 mg/mL when reconstituted to 10 mL,... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial NDC ... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Sterile Diluent for Epoprostenol Sodium for Injection, 50 mL vial (NDC 0703-9... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | MethyIPREDNISolone Acetate Injectable Suspension USP, 40 mg/mL, 1 mL Single... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Feb 10, 2021 | Leucovorin Calcium for Injection, USP, 350 mg/vial, Rx only, labeled as a) Te... | Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... | Class II | Teva Pharmaceuticals USA |
| Dec 21, 2020 | Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose... | Lack of assurance of sterility: The results of sterility tests of seven batches of product were o... | Class II | Merck Sharp & Dohme |
| Dec 17, 2020 | labetalol HCl 20 mg/4 mL, Injection for Intravenous Use (5mg/mL), Rx Only, 4... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Lidocaine HCl 2% 5 mL, 20 mg/mL, Rx Only, 5 mL syringe, Rx Only, SCA Pharmace... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Atropine Sulfate Injection, 0.8 mg/2 mL (0.4 mg/mL), 2 mL Single Dose Syringe... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | morphine sulfate 150 mg/30 mL in 0.9% Sodium Chloride Injection, (5 mg/mL), R... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | PHENYLephrine HCl 800 mcg/10 mL in 0.9% Sodium Chloride (80 mcg/mL), Rx Only,... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Lidocaine HCl 1% 10 mL (10mg/ml), Rx Only, 1 mL Single Dose Syringe, SCA Pha... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Sodium Citrate 4% 3 mL Anticoagulation Solution (40mg/mL), Rx only, 3 mL Sing... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | fentaNYL 1500 mcg/30 mL (50 mcg/mL), 30 mL Single Dose Syringe, Rx Only, SCA ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | ePHEDrine Sulfate 50 mg/10mL in 0.9% Sodium Chloride Injection, 10 mL Single ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | fentaNYL 100 mcg/50mL Ropivacaine HCl 0.1% in 0.9% Sodium Chloride 50 mL, 50 ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | PHENYLephrine HCl 500 mcg/5mL in 0.9% Sodium Chloride (100 mcg/mL), Rx Only, ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Morphine Sulfate 3 mg/3 mL in 0.9% Sodium Chloride (1mg/mL) CII, Rx Only, 3 m... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class III | SCA Pharmaceuticals |
| Dec 17, 2020 | neostigmine methylsulfate 5 mg/5 mL, (1mg/ml), Rx Only, 5 mL Single Dose Syr... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | SUCcinylcholine Chloride 100 mg/5mL, Rx Only, 5 mL Single Dose Syringe, SCA P... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Glycopyrrolate 1 mg/5mL (0.2mg/mL), 5 mL Single Dose Syringe, Rx Only, SCA P... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | ePHEDrine Sulfate, 50 mg/5mL in 0.9% Sodium Chloride Injection, 5 mL Single D... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | HYDROmorphone HCl 6 mg/30mL in 0.9% Sodium Chloride Injection (0.2 mg/mL), Rx... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | fentaNYL 100 mcg/50mL Bupivacaine HCl 0.125% in 0.9% Sodium Chloride 50 mL, 5... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1m... | Lack of assurance of sterility: 13 vials were discovered to have faulty crimps. | Class II | Imprimis NJOF, LLC |
| Dec 17, 2020 | PHENYLephrine HCl 5000 mg/50 mL in Sodium Chloride 0.9% (100 mcg/mL) Rx Only,... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Ketamine 50 mg/5mL in 0.9% Sodium Chloride Injection (10 mg/mL), CII, Rx Only... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | HYDROmorphone HCl 10mg/50mL in 0.9% Sodium Chloride Injection, CII, Rx Only, ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Ketamine 100 mg/10mL in 0.9% Sodium Chloride Injection (10 mg/mL), CII, Rx On... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | SUCccinylcholine Chloride 200 mg/10 mL, (20 mg/mL), Rx Only, 10 mL Single Dos... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | fentaNYL 100 mcg/2mL Injection for IV or IM Use, 2 mL Single Dose Syringe, CI... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Buffered Lidocaine HCl, 1%, 5 mL (10mg/mL) with Sodium Bicarbonate Injection ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | HYDROmorphone HCl 30 mg/30 mL in 0.9% Sodium Chloride Injection (1 mg/mL) a) ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Rocuronium Br 100 mg/10mL (10 mg/mL), Rx Only, 10 mL Single Dose Syringe, SCA... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Rocuronium Br 50 mg/5mL (10 mg/mL), a) 5 mL Single Dose Syringe Red Label(bar... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | Esmolol HCl 100 mg/10 mL (10mg/ mL), 10 mL Single Dose Syringe, Rx Only, SCA... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
| Dec 17, 2020 | ePHEDrine 25 mg/5 mL in 0.9% Sodium Chloride Injection, Rx Only, 5 mL Single ... | Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integra... | Class II | SCA Pharmaceuticals |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.